Table 1.

Clinical characteristics and outcomes of 251 patients by methylation profile

Feature
Nonmethylated group, n = 57, %
Methylated group A, n = 104, %
Methylated group B, n = 90, %
Age*    
    Younger than 15 years   61   46   45  
    Older than 15 years   39   54   55  
Sex, M/F   56/44   60/40   63/37  
WBC count*    
    Lower than 50 × 109/L   76   75   63  
    Higher than 50 × 109/L   24   25   37  
FAB classification    
    L1   38   40   25  
    L2   50   56   64  
    L3   12   4   11  
Blast lineage    
    B   88   76   64  
    T   12   24   36  
NCI risk group    
    Standard   80   76   65  
    Poor   20   24   35  
PETHEMA risk group    
    Standard   40   47   34  
    Poor   60   53   66  
Treatment    
    PETHEMA 89   20   21   20  
    PETHEMA 93   80   79   80  
BMT   14   17   20  
Best response, CR   91   93   88  
Cytogenetic/molecular abnormalities    
    BCR/ABL  21   20   12  
    4(1;19)   4   2   2  
    11q23   3   3   3  
    c-Myc   6   3   8  
    7q35-14q11   6   6   5  
    Hyperdiploidy   9   6   5  
    TEL-AML1  5   16   18  
    None   42   39   40  
    Others   3   3   3  
    NT   1   2   2  
Relapse†  17   51   59  
Death‡
 		 28
 		 43
 		 61
 
Feature
Nonmethylated group, n = 57, %
Methylated group A, n = 104, %
Methylated group B, n = 90, %
Age*    
    Younger than 15 years   61   46   45  
    Older than 15 years   39   54   55  
Sex, M/F   56/44   60/40   63/37  
WBC count*    
    Lower than 50 × 109/L   76   75   63  
    Higher than 50 × 109/L   24   25   37  
FAB classification    
    L1   38   40   25  
    L2   50   56   64  
    L3   12   4   11  
Blast lineage    
    B   88   76   64  
    T   12   24   36  
NCI risk group    
    Standard   80   76   65  
    Poor   20   24   35  
PETHEMA risk group    
    Standard   40   47   34  
    Poor   60   53   66  
Treatment    
    PETHEMA 89   20   21   20  
    PETHEMA 93   80   79   80  
BMT   14   17   20  
Best response, CR   91   93   88  
Cytogenetic/molecular abnormalities    
    BCR/ABL  21   20   12  
    4(1;19)   4   2   2  
    11q23   3   3   3  
    c-Myc   6   3   8  
    7q35-14q11   6   6   5  
    Hyperdiploidy   9   6   5  
    TEL-AML1  5   16   18  
    None   42   39   40  
    Others   3   3   3  
    NT   1   2   2  
Relapse†  17   51   59  
Death‡
 		 28
 		 43
 		 61
 

Methylated group A indicates patients with 1, 2, or 3 methylated genes; methylated group B, patients with more than 3 methylated genes.

WBC indicates white blood cell; FAB, French-American-British; NCI, National Cancer Institute; PETHEMA, Programa para el estudio y tratamiento de las hemopatias malignas; BMT, bone marrow transplantation; CR, complete remission; and NT, not tested.

*

P = .09.

†

P < .0001.

‡

P < .001.

View Large